EMJ Respiratory 13 [Supplement 2] . 2025

In this issue

Our latest symposium review summarises several Boehringer Ingelheim presentations and posters on the role of nerandomilast, an oral investigational phosphodiesterase 4B inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).